Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18462 ↗At a glance
Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Laurent Lam and 3 co-authors. Institution: Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, France. Major MEDLINE topics: Hepatitis B, Chronic, Tenofovir, Antiviral Agents, Guanine. Cited 2 times so far (Crossref); 35 references.
Abstract (original language)
Background
Conflicting results have been reported on the impact of tenofovir versus entecavir on liver‐related outcomes.
Aims
To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)–infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.
Methods
We used the French National Health Insurance Databases (SNDS) to identify HBV‐infected patients. We quantified the excess clinical burden from 2012 to 2021 by comparing the HBV‐infected cohort with a general population cohort, using 1:1 exact matching on birth date, sex, social deprivation index and follow‐up start date. The risks of mortality, HCC and LT were compared between patients treated with tenofovir and entecavir using inverse probability weighting.
Results
A total of 101,740 patients were matched to the general population. From 2012 to 2021, the average annual decreases in excess mortality, incidence of HCC and LT were 3.7%, 8.0% and 11.9%, respectively ( p for trend < 0.001). During the same period, the nucleos(t)ide analog (NUC) treatment coverage significantly increased, particularly after 2016 ( p < 0.001). Among 14,054 treatment‐naïve patients starting tenofovir ( n = 7426) or entecavir ( n = 6628), we observed no difference in the composite outcome of mortality, LT or HCC (HR, 1.09; 95% CI, 0.95–1.24). Tenofovir was associated with an increased risk of HCC compared with entecavir (HR, 1.31; 95% CI, 1.07–1.62).
Conclusions
Tenofovir was associated with a higher risk of HCC compared with entecavir, although no difference in the composite outcome of mortality or liver‐related events was observed between the two treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, France.
- Department of Hepatology and Gastroenterology, Hôpital Saint Joseph & INSERM, UMR 1252 IRD SESSTIM, Aix Marseille Université, Marseille, France.
- AP-HP, Centre Université Paris Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico-chirurgicales, Service des Maladies du Foie & Université Paris Cité, Paris, France.
- Sorbonne Université, Department of Public Health, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.
ORCID profiles: Laurent Lam, Stanislas Pol
Cite
APA
Lam, L., Bourlière, M., Pol, S., & Carrat, F. (2025). Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18462
Vancouver
Lam L, Bourlière M, Pol S, Carrat F. Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18462
BibTeX
@article{Lam2025,
author = {Lam, Laurent and Bourlière, Marc and Pol, Stanislas and Carrat, Fabrice},
title = {Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18462}
}
EUVIMED